Can-Fite BioPharma Achieves 50% Enrollment Milestone in Pancreatic Cancer Phase 2a Study

SEC Filing 6-K (0001213900-25-068944)

Can-Fite BioPharma Ltd. announced on July 30, 2025, that it has achieved over 50% enrollment in its Phase 2a trial of Namodenoson for pancreatic cancer. The study is a multicenter, open-label trial evaluating the safety, clinical activity, and pharmacokinetics of Namodenoson in patients with advanced pancreatic adenocarcinoma. The primary endpoint is safety, and Namodenoson has demonstrated a favorable safety profile to date. The study is led by Prof. Salomon Stemmer at the Davidoff Center, Rabin Medical Center, Israel. Namodenoson is a highly selective A3 adenosine receptor agonist with anti-tumor activity in preclinical models and has received Orphan Drug Designation from the FDA for pancreatic cancer.